TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion
M25-204
Phase 2 small_molecule active
Quick answer
TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion for Urothelial Carcinoma, Metastatic Urothelial Carcinoma is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Urothelial Carcinoma, Metastatic Urothelial Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active